Protara Therapeutics, Inc. (TARA) posted a Q4 2025 loss of $0.37 per share, narrower than the $0.48 per share loss reported in the year-ago quarter. The clinical-stage biopharmaceutical company continues to advance its lead program TARA-002, an investigational cell therapy currently in Phase II clinical trials for non-muscle invasive bladder cancer and lymphatic malformations.
The company focuses on developing transformative therapies for the treatment of cancer and rare diseases. The wider-than-expected loss reflects ongoing clinical development expenses as Protara progresses its pipeline programs.
A detailed analysis of Protara Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.